GenSight Biologics reports 'promising' clinical trial results for GS010.
M2 PHARMA-June 14, 2017-GenSight Biologics reports 'promising' clinical trial results for GS010
(C)2017 M2 COMMUNICATIONS
French biopharma firm GenSight Biologics (EPA: SIGHT) has published additional promising clinical trial results with GS010 after 96 weeks of follow-up in its Phase I/II study, the company reported on Wednesday.
GenSight, which focuses on the discovery and development of innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, said that these results confirm earlier theories.
The results indicate long-term positive sustained visual acuity gain after two years with a single intravitreal injection of GS010 in patients with Leber's Hereditary Optic Neuropathy (LHON), especially in patients with less than two years of disease onset.
Dr Catherine Vignal, investigator of the study and chief of the Department of Ophthalmology at the Rothschild Foundation Hospital in Paris, commented: "The confirmatory safety and continued positive trends after two years of follow-up confirm significant hope for patients suffering from LHON.
"It is worth noting that the observed improvement in some of the untreated eyes was consistent with several prior studies in neuroretinal degenerative diseases. The insights gained from this and forthcoming data will be tremendously helpful as GenSight works to develop a therapy for this very severe disease with no existing curative treatment."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Jun 14, 2017|
|Previous Article:||STADA orders Enzymatica's ColdZyme Mouth spray for German, Belgian and Austrian markets.|
|Next Article:||Starpharma sells agrochemicals and Priostar business to Agrium.|